Phenotypes Associated with This Genotype

Genotype
MGI:6467230

• Allelic Composition: Slc16a3^tm1Tac/Slc16a3^tm1Tac
• Genetic Background: B6NTac.Cg-Slc16a3^tm1Tac/Tac

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

nervous system

abnormal axon morphology ( J:288233 )

• tamoxifen-treated mice exhibit a small increase in axon diameter with increased occurrence of large axons compared with control mice

• however, normal myelinated axon density

abnormal neuromuscular synapse morphology ( J:288233 )

• increased disrupted NMJs in the EDL of 12 month old tamoxifen-treated mice indicating denervation and re-innervation with only a minimum number of NMJs showing partial denervation

• however, NMJs are normal at 6 months of age

abnormal action potential ( J:288233 )

• neuromuscular junctions exhibit lower compound muscle action potential amplitude (expressed as root mean squared) in tamoxifen-treated mice

• however, amplitude decrement after 30 s of repetitive stimulation is normal

homeostasis/metabolism

impaired exercise endurance ( J:288233 )

• 2.5-fold reduction in run distance

• quicker accumulation of electric shocks over time at high-intensity performance

muscle

muscle phenotype ( J:288233 )

N • intrinsic skeletal muscle properties (muscle contractility or fatigability) are normal

behavior/neurological

impaired exercise endurance ( J:288233 )

• 2.5-fold reduction in run distance

• quicker accumulation of electric shocks over time at high-intensity performance